MX2023003929A - Anticuerpos cd1a y su uso. - Google Patents

Anticuerpos cd1a y su uso.

Info

Publication number
MX2023003929A
MX2023003929A MX2023003929A MX2023003929A MX2023003929A MX 2023003929 A MX2023003929 A MX 2023003929A MX 2023003929 A MX2023003929 A MX 2023003929A MX 2023003929 A MX2023003929 A MX 2023003929A MX 2023003929 A MX2023003929 A MX 2023003929A
Authority
MX
Mexico
Prior art keywords
antibodies
cd1a
cd1a antibodies
antigen
binding fragments
Prior art date
Application number
MX2023003929A
Other languages
English (en)
Inventor
Chew Shun Chang
Di Wu
Florian Winau
Oleg V Kovalenko
Nicholas Andrew Marze
Shian- Huey Chiang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2023003929A publication Critical patent/MX2023003929A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan anticuerpos, y fragmentos de unión a antígeno de los mismos, que se unen específicamente al Clúster de Diferenciación 1a (CD1a); las formas de realización incluyen usos y métodos asociados de uso de anticuerpos y fragmentos de unión a antígeno de los mismos.
MX2023003929A 2020-10-09 2021-10-07 Anticuerpos cd1a y su uso. MX2023003929A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063090055P 2020-10-09 2020-10-09
PCT/US2021/071779 WO2022077021A1 (en) 2020-10-09 2021-10-07 CD1a ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2023003929A true MX2023003929A (es) 2023-06-22

Family

ID=78517004

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003929A MX2023003929A (es) 2020-10-09 2021-10-07 Anticuerpos cd1a y su uso.

Country Status (16)

Country Link
US (2) US11746154B2 (es)
EP (1) EP4225437A1 (es)
JP (1) JP2023545075A (es)
KR (1) KR20230084212A (es)
CN (1) CN116710481A (es)
AR (1) AR123728A1 (es)
AU (1) AU2021358662A1 (es)
BR (1) BR112023005980A2 (es)
CA (1) CA3198072A1 (es)
CO (1) CO2023004381A2 (es)
IL (1) IL301625A (es)
MX (1) MX2023003929A (es)
PE (1) PE20240589A1 (es)
TW (1) TWI826839B (es)
WO (1) WO2022077021A1 (es)
ZA (1) ZA202305072B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202217923D0 (en) 2022-11-29 2023-01-11 Univ Oxford Innovation Ltd Antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364933A (en) 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human thymocyte antigen and methods of preparing same
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
AU2063197A (en) 1996-03-04 1997-09-22 Massachusetts Institute Of Technology Materials and methods for enhancing cellular internalization
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
ATE287257T1 (de) 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
JP2002518432A (ja) 1998-06-24 2002-06-25 アドバンスト インハレーション リサーチ，インコーポレイテッド 吸入器から放出される大多孔性粒子
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005063819A2 (en) 2003-12-23 2005-07-14 Crucell Holland B.V. Human binding molecule against cd1a
US10844118B2 (en) * 2013-09-20 2020-11-24 Children's Medical Center Corporation Treatment of inflammatory skin disease
US10647756B2 (en) 2015-05-18 2020-05-12 Pfizer Inc. Humanized antibodies
EP3696191A1 (en) 2019-02-14 2020-08-19 Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) Car t-cells for the treatment of cd1a-positive cancer

Also Published As

Publication number Publication date
AU2021358662A1 (en) 2023-05-04
US20220112291A1 (en) 2022-04-14
PE20240589A1 (es) 2024-03-21
US11746154B2 (en) 2023-09-05
CN116710481A (zh) 2023-09-05
WO2022077021A1 (en) 2022-04-14
TW202229334A (zh) 2022-08-01
CO2023004381A2 (es) 2023-04-27
AR123728A1 (es) 2023-01-04
ZA202305072B (en) 2024-01-31
CA3198072A1 (en) 2022-04-14
BR112023005980A2 (pt) 2023-05-02
TWI826839B (zh) 2023-12-21
EP4225437A1 (en) 2023-08-16
JP2023545075A (ja) 2023-10-26
KR20230084212A (ko) 2023-06-12
IL301625A (en) 2023-05-01
US20240076382A1 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
WO2018234793A3 (en) Antibodies
WO2019008123A3 (en) CELLS, VERTEBRATES, POPULATIONS AND METHODS
WO2019224716A3 (en) Antibodies specific for gucy2c and uses thereof
AU2017297138A8 (en) Anti-PD-1 antibodies, method for producing same and method for using same
PH12020552229A1 (en) Il-11ra antibodies
WO2019014328A3 (en) AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
MX2022006578A (es) Anticuerpos especificos para cd47, pd-l1 y sus usos.
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
MX2022002682A (es) Anticuerpos anti-cd73.
WO2018194496A3 (ru) Моноклональное антитело к pd-l1
MX2021014973A (es) Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso.
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
JOP20200295A1 (ar) أجسام أحادية النوعية ومتعددة النوعية مضادة لـ tmeff2 المضاد واستخداماتها
MX2021009079A (es) Metodos para tratar el mieloma multiple.
ZA202305072B (en) Cd1a antibodies and uses thereof
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
MX2021015156A (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.
MX2023014458A (es) Anticuerpos anti-ccr8 y usos de los mismos.
WO2020123330A3 (en) Anti-alpha-synuclein antibodies and uses thereof
WO2019100052A3 (en) Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
CR20220061A (es) Anticuerpos que se unen a células cancerosas y que dirigen radionucleidos a dichas células
MX2021015301A (es) Métodos de cultivo celular y composiciones para la producción de anticuerpos.